Sorafenib-13C,d3
Based on 1 publication(s) in Google Scholar
Sorafenib-13C,d3 is the 13C- and deuterium labeled Sorafenib. Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator.
For research use only. We do not sell to patients.
- Purity: 98.35%
- CAS No.: 1210608-86-8
- Formula: C2013CH13D3ClF3N4O3
- Molecular Weight:468.84
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Sorafenib-13C,d3
More
Customer Validation & Images
-
Cell Proliferation/Viability Assay
All VEGFR Isoforms
More
Biological Activity
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 1210608-86-8
-
Unlabeled Cas 284461-73-0
-
Appearance Solid
-
Molecular Weight 468.84
-
Formula C2013CH13D3ClF3N4O3
-
Color Off-white to gray
-
SMILES
O=C(NC(C=C1)=CC=C1OC2=CC(C(N[13C]([2H])([2H])[2H])=O)=NC=C2)NC3=CC=C(Cl)C(C(F)(F)F)=C3
-
Synonyms
Bay 43-9006-13C,d3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
BMC Cancer
IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways. [Abstract]2023 Jan 25;23(1):87. PMID: 36698167
Sorafenib-13C,d3 purchased from MedChemExpress. Usage Cited in: BMC Cancer. 2023 Jan 25;23(1):87. [Abstract]
Sorafenib-13C,d3 (SFB; 4 µM) shows inhibition on the clone formation efficiency of HCC cells.
Solvent & Solubility
DMSO : 16.67 mg/mL (35.56 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
[2]. Wilhelm SM, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 Oct 1;64(19):7099-109. [Content Brief]
[3]. El-Ashmawy NE, et al. Sorafenib effect on liver neoplastic changes in rats: more than a kinase inhibitor. Clin Exp Med. 2016 Apr 16. [Content Brief]
[4]. Jin W, et al. Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1. Oncol Rep. 2017 Jan;37(1):273-280. [Content Brief]
[5]. Li M, et al. Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer. Br J Cancer. 2017 Aug 29. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1329 mL | 10.6646 mL | 21.3292 mL | 53.3231 mL |
| 5 mM | 0.4266 mL | 2.1329 mL | 4.2658 mL | 10.6646 mL | |
| 10 mM | 0.2133 mL | 1.0665 mL | 2.1329 mL | 5.3323 mL | |
| 15 mM | 0.1422 mL | 0.7110 mL | 1.4219 mL | 3.5549 mL | |
| 20 mM | 0.1066 mL | 0.5332 mL | 1.0665 mL | 2.6662 mL | |
| 25 mM | 0.0853 mL | 0.4266 mL | 0.8532 mL | 2.1329 mL | |
| 30 mM | 0.0711 mL | 0.3555 mL | 0.7110 mL | 1.7774 mL |
Sorafenib-13C,d3 Related Classifications
HY-10201S2 Related Classifications
Powered by Bioz